+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Tofacitinib Citrate Extended-Release Tablets Market - Global Forecast 2026-2032- Product Image
Tofacitinib Citrate Extended-Release Tablets Market - Global Forecast 2026-2032- Product Image
Sale

Tofacitinib Citrate Extended-Release Tablets Market - Global Forecast 2026-2032

  • Report

  • 199 Pages
  • September 2026
  • Region: Global
  • 360iResearch™
  • ID: 6082105
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Tofacitinib Citrate Extended-Release Tablets Market is projected to reach USD 1.44 Billion in 2026. It is expected to continue growing at a CAGR of 9.09%, reaching USD 2.43 Billion by 2032.

Introduction to Tofacitinib Citrate Extended-Release Tablets

Tofacitinib citrate extended-release tablets are an oral Janus kinase (JAK) inhibitor formulation designed to provide once-daily administration. Tofacitinib is approved in several jurisdictions for selected inflammatory and autoimmune conditions, with indications and prescribing restrictions varying by regulator. Clinical use requires attention to infection risk, laboratory monitoring, cardiovascular risk, malignancy warnings, and thromboembolic concerns described in applicable product labeling.

Regulatory and Clinical Shifts Reshaping Use

The landscape is being shaped by tighter risk management for JAK inhibitors, including boxed warnings or equivalent safety communications in major jurisdictions. Regulators and clinical guidelines increasingly emphasize individualized treatment selection, prior therapy history, age, cardiovascular and thrombotic risk, vaccination status, and monitoring of blood counts, liver enzymes, and lipids. Extended-release dosing may support adherence, but it does not remove the need for indication-specific evaluation or ongoing safety surveillance.

Artificial Intelligence and Evidence-Based Care Pathways

Artificial intelligence can support, but not replace, clinical judgment in this therapy area. Potential applications include identifying patients needing laboratory follow-up, detecting medication-related safety signals in electronic health records, assisting adverse-event review, and improving trial recruitment for immune-mediated diseases. Responsible deployment requires validated data, transparent performance testing, protection of patient information, and clinician oversight because algorithmic outputs may be affected by incomplete records or unequal representation across populations.

Regional Insights Across Six Healthcare Landscapes

North America combines mature specialty-care infrastructure with prominent regulatory scrutiny of JAK-inhibitor safety and treatment positioning. Europe emphasizes centralized and national evidence assessment, risk minimization, and health-system prescribing criteria. Asia-Pacific presents varied regulatory pathways, reimbursement arrangements, and access conditions across advanced and emerging systems. Latin America is characterized by heterogeneous formularies, procurement practices, and specialist availability. The Middle East is influenced by concentrated specialist services and country-specific reimbursement policies, while Africa faces wider variation in diagnostic capacity, monitoring access, procurement continuity, and availability of rheumatology and dermatology services.

Group Insights: ASEAN, BRICS, EU, G7, GCC, and NATO

ASEAN markets differ substantially in regulatory maturity, reimbursement, and specialist access, making local evidence and supply planning important. BRICS members reflect diverse public-sector procurement models and uneven laboratory and specialty-care capacity. The European Union is shaped by shared regulatory processes alongside national pricing and reimbursement decisions. G7 health systems generally have stronger pharmacovigilance and treatment-monitoring infrastructure but apply distinct clinical and access policies. GCC countries often combine centralized purchasing with highly specialized care networks, whereas NATO membership does not create a single medicines policy; its relevance is primarily contextual for preparedness, logistics, and health-system resilience.

Country Insights for Fifteen Priority Markets

The United States and Canada apply detailed safety labeling and established specialty-care pathways, with coverage decisions varying by payer. The United Kingdom, France, Germany, Italy, and Spain combine robust regulatory oversight with national or regional health-technology and reimbursement processes. Australia and Japan maintain structured regulatory and prescribing systems, while South Korea and China continue to reflect locally defined approval, reimbursement, and monitoring requirements. India, Brazil, Mexico, and Russia show greater variation in public and private access, procurement, specialist availability, and laboratory follow-up. Across all countries, indication-specific approval, patient risk assessment, and reliable monitoring remain central to responsible use.

Actions for Leaders in Safety, Access, and Adherence

Industry leaders should align evidence generation with approved indications, comparative clinical needs, and regulator-defined safety questions. Strengthening pharmacovigilance, clear risk communication, educational support for laboratory monitoring, and adherence services can improve appropriate use. Regional strategies should account for reimbursement rules, local treatment guidelines, supply continuity, and diagnostic capacity rather than assuming uniform adoption. Any digital or AI-enabled tool should undergo clinical validation, privacy review, bias assessment, and post-deployment monitoring before integration into care pathways.

Research Methodology for the Executive Summary

This summary uses the supplied market definition-Tofacitinib Citrate Extended-Release Tablets-and synthesizes established regulatory, clinical, and health-system considerations without presenting market estimates, forecasts, shares, or company-specific claims. The geographic discussion is organized around the required regions, groups, and countries. Interpretations are limited to broadly documented characteristics of tofacitinib use, JAK-inhibitor risk management, and differences in healthcare delivery; product indications and restrictions should be verified against current local labeling and guidance.

Conclusion: Responsible Positioning in a Risk-Sensitive Market

Tofacitinib citrate extended-release tablets occupy a clinically established but closely monitored segment of oral immunomodulatory therapy. Future effectiveness in practice will depend less on formulation convenience alone than on appropriate patient selection, adherence to local labeling, laboratory surveillance, pharmacovigilance, and equitable access to specialist care. Leaders that combine rigorous safety governance with regionally tailored evidence and support programs will be better positioned to promote responsible treatment use across diverse healthcare systems.

This product will be delivered within 1-3 business days.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. New Revenue Opportunities
3.4. Next-Generation Business Models
3.5. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Tofacitinib Citrate Extended-Release Tablets Market, by Indication
7.1. Introduction
7.2. Psoriatic Arthritis
7.3. Rheumatoid Arthritis
7.4. Ulcerative Colitis
8. Tofacitinib Citrate Extended-Release Tablets Market, by Patient Age Group
8.1. Introduction
8.2. Adults
8.3. Geriatric
8.4. Pediatric
9. Tofacitinib Citrate Extended-Release Tablets Market, by Distribution Channel
9.1. Introduction
9.2. Hospital Pharmacy
9.2.1. Private Hospital Pharmacy
9.2.2. Public Hospital Pharmacy
9.3. Online Pharmacy
9.4. Retail Pharmacy
9.4.1. Chain Pharmacy
9.4.2. Independent Pharmacy
9.5. Specialty Pharmacy
9.5.1. Hospital Owned Specialty Pharmacy
9.5.2. Independent Specialty Pharmacy
10. Tofacitinib Citrate Extended-Release Tablets Market, by End User
10.1. Introduction
10.2. Ambulatory Care Centers
10.3. Hospitals
10.4. Specialty Clinics
11. Tofacitinib Citrate Extended-Release Tablets Market, by Region
11.1. Introduction
11.2. Asia-Pacific
11.3. North America
11.4. Latin America
11.5. Europe
11.6. Middle East
11.7. Africa
12. Tofacitinib Citrate Extended-Release Tablets Market, by Group
12.1. Introduction
12.2. ASEAN
12.3. GCC
12.4. European Union
12.5. BRICS
12.6. G7
12.7. NATO
13. Tofacitinib Citrate Extended-Release Tablets Market, by Country
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. United Kingdom
13.7. Germany
13.8. France
13.9. Russia
13.10. Italy
13.11. Spain
13.12. China
13.13. India
13.14. Japan
13.15. Australia
13.16. South Korea
14. Competitive Landscape
14.1. Market Share Analysis, 2025
14.2. Market Concentration Analysis, 2025
14.2.1. Concentration Ratio (CR)
14.2.2. Herfindahl Hirschman Index (HHI)
14.3. Recent Developments & Impact Analysis, 2025
14.4. Product Portfolio Analysis, 2025
14.5. Benchmarking Analysis, 2025
15. Company Profiles
15.1. Apotex Corp.
15.2. Aurobindo Pharma Limited
15.3. Cipla Limited
15.4. Delvin Formulations Pvt Ltd.
15.5. Dr. Reddy’s Laboratories Limited
15.6. Glenmark Pharmaceuticals Limited
15.7. Lupin Limited
15.8. Mylan Pharmaceuticals, Inc.
15.9. Pfizer Inc.
15.10. Sandoz Inc.
15.11. Teva Pharmaceuticals USA, Inc.
16. Key Experts
LIST OF FIGURES
FIGURE 1. Global Tofacitinib Citrate Extended-Release Tablets Market, Years Considered for the Study
FIGURE 2. Global Tofacitinib Citrate Extended-Release Tablets Market, Research Design
FIGURE 3. Global Tofacitinib Citrate Extended-Release Tablets Market, Research Framework
FIGURE 4. Global Tofacitinib Citrate Extended-Release Tablets Market, Data Triangulation
FIGURE 5. Global Tofacitinib Citrate Extended-Release Tablets Market Size, 2017-2032 (USD Million)
FIGURE 6. Global Tofacitinib Citrate Extended-Release Tablets Market Size, by Indication, 2025 vs 2032 (%)
FIGURE 7. Global Tofacitinib Citrate Extended-Release Tablets Market Size, by Indication, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 8. Global Tofacitinib Citrate Extended-Release Tablets Market Size, by Patient Age Group, 2025 vs 2032 (%)
FIGURE 9. Global Tofacitinib Citrate Extended-Release Tablets Market Size, by Patient Age Group, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 10. Global Tofacitinib Citrate Extended-Release Tablets Market Size, by Distribution Channel, 2025 vs 2032 (%)
FIGURE 11. Global Tofacitinib Citrate Extended-Release Tablets Market Size, by Distribution Channel, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 12. Global Tofacitinib Citrate Extended-Release Tablets Market Size, by End User, 2025 vs 2032 (%)
FIGURE 13. Global Tofacitinib Citrate Extended-Release Tablets Market Size, by End User, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 14. Global Tofacitinib Citrate Extended-Release Tablets Market Size, by Region, 2025 vs 2032 (%)
FIGURE 15. Global Tofacitinib Citrate Extended-Release Tablets Market Size, by Region, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 16. Global Tofacitinib Citrate Extended-Release Tablets Market Size, by Group, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 17. Global Tofacitinib Citrate Extended-Release Tablets Market Size, by Country, 2025 vs 2032 (%)
FIGURE 18. Global Tofacitinib Citrate Extended-Release Tablets Market Size, by Country, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 19. Global Tofacitinib Citrate Extended-Release Tablets Market Share, by Key Player, 2025
LIST OF TABLES
TABLE 1. Global Tofacitinib Citrate Extended-Release Tablets Market Segmentation & Coverage
TABLE 2. Global Tofacitinib Citrate Extended-Release Tablets Market Size, 2017-2032 (USD Million)
TABLE 3. Global Tofacitinib Citrate Extended-Release Tablets Market Size, by Indication, 2017-2032 (USD Million)
TABLE 4. Global Psoriatic Arthritis Market Size, by Region, 2017-2032 (USD Million)
TABLE 5. Global Psoriatic Arthritis Market Size, by Group, 2017-2032 (USD Million)
TABLE 6. Global Psoriatic Arthritis Market Size, by Country, 2017-2032 (USD Million)
TABLE 7. Global Rheumatoid Arthritis Market Size, by Region, 2017-2032 (USD Million)
TABLE 8. Global Rheumatoid Arthritis Market Size, by Group, 2017-2032 (USD Million)
TABLE 9. Global Rheumatoid Arthritis Market Size, by Country, 2017-2032 (USD Million)
TABLE 10. Global Ulcerative Colitis Market Size, by Region, 2017-2032 (USD Million)
TABLE 11. Global Ulcerative Colitis Market Size, by Group, 2017-2032 (USD Million)
TABLE 12. Global Ulcerative Colitis Market Size, by Country, 2017-2032 (USD Million)
TABLE 13. Global Tofacitinib Citrate Extended-Release Tablets Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 14. Global Adults Market Size, by Region, 2017-2032 (USD Million)
TABLE 15. Global Adults Market Size, by Group, 2017-2032 (USD Million)
TABLE 16. Global Adults Market Size, by Country, 2017-2032 (USD Million)
TABLE 17. Global Geriatric Market Size, by Region, 2017-2032 (USD Million)
TABLE 18. Global Geriatric Market Size, by Group, 2017-2032 (USD Million)
TABLE 19. Global Geriatric Market Size, by Country, 2017-2032 (USD Million)
TABLE 20. Global Pediatric Market Size, by Region, 2017-2032 (USD Million)
TABLE 21. Global Pediatric Market Size, by Group, 2017-2032 (USD Million)
TABLE 22. Global Pediatric Market Size, by Country, 2017-2032 (USD Million)
TABLE 23. Global Tofacitinib Citrate Extended-Release Tablets Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 24. Global Hospital Pharmacy Market Size, by Region, 2017-2032 (USD Million)
TABLE 25. Global Hospital Pharmacy Market Size, by Group, 2017-2032 (USD Million)
TABLE 26. Global Hospital Pharmacy Market Size, by Country, 2017-2032 (USD Million)
TABLE 27. Global Private Hospital Pharmacy Market Size, by Region, 2017-2032 (USD Million)
TABLE 28. Global Private Hospital Pharmacy Market Size, by Group, 2017-2032 (USD Million)
TABLE 29. Global Private Hospital Pharmacy Market Size, by Country, 2017-2032 (USD Million)
TABLE 30. Global Public Hospital Pharmacy Market Size, by Region, 2017-2032 (USD Million)
TABLE 31. Global Public Hospital Pharmacy Market Size, by Group, 2017-2032 (USD Million)
TABLE 32. Global Public Hospital Pharmacy Market Size, by Country, 2017-2032 (USD Million)
TABLE 33. Global Online Pharmacy Market Size, by Region, 2017-2032 (USD Million)
TABLE 34. Global Online Pharmacy Market Size, by Group, 2017-2032 (USD Million)
TABLE 35. Global Online Pharmacy Market Size, by Country, 2017-2032 (USD Million)
TABLE 36. Global Retail Pharmacy Market Size, by Region, 2017-2032 (USD Million)
TABLE 37. Global Retail Pharmacy Market Size, by Group, 2017-2032 (USD Million)
TABLE 38. Global Retail Pharmacy Market Size, by Country, 2017-2032 (USD Million)
TABLE 39. Global Chain Pharmacy Market Size, by Region, 2017-2032 (USD Million)
TABLE 40. Global Chain Pharmacy Market Size, by Group, 2017-2032 (USD Million)
TABLE 41. Global Chain Pharmacy Market Size, by Country, 2017-2032 (USD Million)
TABLE 42. Global Independent Pharmacy Market Size, by Region, 2017-2032 (USD Million)
TABLE 43. Global Independent Pharmacy Market Size, by Group, 2017-2032 (USD Million)
TABLE 44. Global Independent Pharmacy Market Size, by Country, 2017-2032 (USD Million)
TABLE 45. Global Specialty Pharmacy Market Size, by Region, 2017-2032 (USD Million)
TABLE 46. Global Specialty Pharmacy Market Size, by Group, 2017-2032 (USD Million)
TABLE 47. Global Specialty Pharmacy Market Size, by Country, 2017-2032 (USD Million)
TABLE 48. Global Hospital Owned Specialty Pharmacy Market Size, by Region, 2017-2032 (USD Million)
TABLE 49. Global Hospital Owned Specialty Pharmacy Market Size, by Group, 2017-2032 (USD Million)
TABLE 50. Global Hospital Owned Specialty Pharmacy Market Size, by Country, 2017-2032 (USD Million)
TABLE 51. Global Independent Specialty Pharmacy Market Size, by Region, 2017-2032 (USD Million)
TABLE 52. Global Independent Specialty Pharmacy Market Size, by Group, 2017-2032 (USD Million)
TABLE 53. Global Independent Specialty Pharmacy Market Size, by Country, 2017-2032 (USD Million)
TABLE 54. Global Tofacitinib Citrate Extended-Release Tablets Market Size, by End User, 2017-2032 (USD Million)
TABLE 55. Global Ambulatory Care Centers Market Size, by Region, 2017-2032 (USD Million)
TABLE 56. Global Ambulatory Care Centers Market Size, by Group, 2017-2032 (USD Million)
TABLE 57. Global Ambulatory Care Centers Market Size, by Country, 2017-2032 (USD Million)
TABLE 58. Global Hospitals Market Size, by Region, 2017-2032 (USD Million)
TABLE 59. Global Hospitals Market Size, by Group, 2017-2032 (USD Million)
TABLE 60. Global Hospitals Market Size, by Country, 2017-2032 (USD Million)
TABLE 61. Global Specialty Clinics Market Size, by Region, 2017-2032 (USD Million)
TABLE 62. Global Specialty Clinics Market Size, by Group, 2017-2032 (USD Million)
TABLE 63. Global Specialty Clinics Market Size, by Country, 2017-2032 (USD Million)
TABLE 64. Global Tofacitinib Citrate Extended-Release Tablets Market Size, by Region, 2017-2032 (USD Million)
TABLE 65. Asia-Pacific Tofacitinib Citrate Extended-Release Tablets Market Size, by Region, 2017-2032 (USD Million)
TABLE 66. Asia-Pacific Tofacitinib Citrate Extended-Release Tablets Market Size, by Indication, 2017-2032 (USD Million)
TABLE 67. Asia-Pacific Tofacitinib Citrate Extended-Release Tablets Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 68. Asia-Pacific Tofacitinib Citrate Extended-Release Tablets Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 69. Asia-Pacific Tofacitinib Citrate Extended-Release Tablets Market Size, by Hospital Pharmacy, 2017-2032 (USD Million)
TABLE 70. Asia-Pacific Tofacitinib Citrate Extended-Release Tablets Market Size, by Retail Pharmacy, 2017-2032 (USD Million)
TABLE 71. Asia-Pacific Tofacitinib Citrate Extended-Release Tablets Market Size, by Specialty Pharmacy, 2017-2032 (USD Million)
TABLE 72. Asia-Pacific Tofacitinib Citrate Extended-Release Tablets Market Size, by End User, 2017-2032 (USD Million)
TABLE 73. North America Tofacitinib Citrate Extended-Release Tablets Market Size, by Region, 2017-2032 (USD Million)
TABLE 74. North America Tofacitinib Citrate Extended-Release Tablets Market Size, by Indication, 2017-2032 (USD Million)
TABLE 75. North America Tofacitinib Citrate Extended-Release Tablets Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 76. North America Tofacitinib Citrate Extended-Release Tablets Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 77. North America Tofacitinib Citrate Extended-Release Tablets Market Size, by Hospital Pharmacy, 2017-2032 (USD Million)
TABLE 78. North America Tofacitinib Citrate Extended-Release Tablets Market Size, by Retail Pharmacy, 2017-2032 (USD Million)
TABLE 79. North America Tofacitinib Citrate Extended-Release Tablets Market Size, by Specialty Pharmacy, 2017-2032 (USD Million)
TABLE 80. North America Tofacitinib Citrate Extended-Release Tablets Market Size, by End User, 2017-2032 (USD Million)
TABLE 81. Latin America Tofacitinib Citrate Extended-Release Tablets Market Size, by Region, 2017-2032 (USD Million)
TABLE 82. Latin America Tofacitinib Citrate Extended-Release Tablets Market Size, by Indication, 2017-2032 (USD Million)
TABLE 83. Latin America Tofacitinib Citrate Extended-Release Tablets Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 84. Latin America Tofacitinib Citrate Extended-Release Tablets Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 85. Latin America Tofacitinib Citrate Extended-Release Tablets Market Size, by Hospital Pharmacy, 2017-2032 (USD Million)
TABLE 86. Latin America Tofacitinib Citrate Extended-Release Tablets Market Size, by Retail Pharmacy, 2017-2032 (USD Million)
TABLE 87. Latin America Tofacitinib Citrate Extended-Release Tablets Market Size, by Specialty Pharmacy, 2017-2032 (USD Million)
TABLE 88. Latin America Tofacitinib Citrate Extended-Release Tablets Market Size, by End User, 2017-2032 (USD Million)
TABLE 89. Europe Tofacitinib Citrate Extended-Release Tablets Market Size, by Region, 2017-2032 (USD Million)
TABLE 90. Europe Tofacitinib Citrate Extended-Release Tablets Market Size, by Indication, 2017-2032 (USD Million)
TABLE 91. Europe Tofacitinib Citrate Extended-Release Tablets Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 92. Europe Tofacitinib Citrate Extended-Release Tablets Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 93. Europe Tofacitinib Citrate Extended-Release Tablets Market Size, by Hospital Pharmacy, 2017-2032 (USD Million)
TABLE 94. Europe Tofacitinib Citrate Extended-Release Tablets Market Size, by Retail Pharmacy, 2017-2032 (USD Million)
TABLE 95. Europe Tofacitinib Citrate Extended-Release Tablets Market Size, by Specialty Pharmacy, 2017-2032 (USD Million)
TABLE 96. Europe Tofacitinib Citrate Extended-Release Tablets Market Size, by End User, 2017-2032 (USD Million)
TABLE 97. Middle East Tofacitinib Citrate Extended-Release Tablets Market Size, by Region, 2017-2032 (USD Million)
TABLE 98. Middle East Tofacitinib Citrate Extended-Release Tablets Market Size, by Indication, 2017-2032 (USD Million)
TABLE 99. Middle East Tofacitinib Citrate Extended-Release Tablets Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 100. Middle East Tofacitinib Citrate Extended-Release Tablets Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 101. Middle East Tofacitinib Citrate Extended-Release Tablets Market Size, by Hospital Pharmacy, 2017-2032 (USD Million)
TABLE 102. Middle East Tofacitinib Citrate Extended-Release Tablets Market Size, by Retail Pharmacy, 2017-2032 (USD Million)
TABLE 103. Middle East Tofacitinib Citrate Extended-Release Tablets Market Size, by Specialty Pharmacy, 2017-2032 (USD Million)
TABLE 104. Middle East Tofacitinib Citrate Extended-Release Tablets Market Size, by End User, 2017-2032 (USD Million)
TABLE 105. Africa Tofacitinib Citrate Extended-Release Tablets Market Size, by Region, 2017-2032 (USD Million)
TABLE 106. Africa Tofacitinib Citrate Extended-Release Tablets Market Size, by Indication, 2017-2032 (USD Million)
TABLE 107. Africa Tofacitinib Citrate Extended-Release Tablets Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 108. Africa Tofacitinib Citrate Extended-Release Tablets Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 109. Africa Tofacitinib Citrate Extended-Release Tablets Market Size, by Hospital Pharmacy, 2017-2032 (USD Million)
TABLE 110. Africa Tofacitinib Citrate Extended-Release Tablets Market Size, by Retail Pharmacy, 2017-2032 (USD Million)
TABLE 111. Africa Tofacitinib Citrate Extended-Release Tablets Market Size, by Specialty Pharmacy, 2017-2032 (USD Million)
TABLE 112. Africa Tofacitinib Citrate Extended-Release Tablets Market Size, by End User, 2017-2032 (USD Million)
TABLE 113. Global Tofacitinib Citrate Extended-Release Tablets Market Size, by Group, 2017-2032 (USD Million)
TABLE 114. ASEAN Tofacitinib Citrate Extended-Release Tablets Market Size, by Group, 2017-2032 (USD Million)
TABLE 115. ASEAN Tofacitinib Citrate Extended-Release Tablets Market Size, by Indication, 2017-2032 (USD Million)
TABLE 116. ASEAN Tofacitinib Citrate Extended-Release Tablets Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 117. ASEAN Tofacitinib Citrate Extended-Release Tablets Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 118. ASEAN Tofacitinib Citrate Extended-Release Tablets Market Size, by Hospital Pharmacy, 2017-2032 (USD Million)
TABLE 119. ASEAN Tofacitinib Citrate Extended-Release Tablets Market Size, by Retail Pharmacy, 2017-2032 (USD Million)
TABLE 120. ASEAN Tofacitinib Citrate Extended-Release Tablets Market Size, by Specialty Pharmacy, 2017-2032 (USD Million)
TABLE 121. ASEAN Tofacitinib Citrate Extended-Release Tablets Market Size, by End User, 2017-2032 (USD Million)
TABLE 122. GCC Tofacitinib Citrate Extended-Release Tablets Market Size, by Group, 2017-2032 (USD Million)
TABLE 123. GCC Tofacitinib Citrate Extended-Release Tablets Market Size, by Indication, 2017-2032 (USD Million)
TABLE 124. GCC Tofacitinib Citrate Extended-Release Tablets Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 125. GCC Tofacitinib Citrate Extended-Release Tablets Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 126. GCC Tofacitinib Citrate Extended-Release Tablets Market Size, by Hospital Pharmacy, 2017-2032 (USD Million)
TABLE 127. GCC Tofacitinib Citrate Extended-Release Tablets Market Size, by Retail Pharmacy, 2017-2032 (USD Million)
TABLE 128. GCC Tofacitinib Citrate Extended-Release Tablets Market Size, by Specialty Pharmacy, 2017-2032 (USD Million)
TABLE 129. GCC Tofacitinib Citrate Extended-Release Tablets Market Size, by End User, 2017-2032 (USD Million)
TABLE 130. European Union Tofacitinib Citrate Extended-Release Tablets Market Size, by Group, 2017-2032 (USD Million)
TABLE 131. European Union Tofacitinib Citrate Extended-Release Tablets Market Size, by Indication, 2017-2032 (USD Million)
TABLE 132. European Union Tofacitinib Citrate Extended-Release Tablets Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 133. European Union Tofacitinib Citrate Extended-Release Tablets Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 134. European Union Tofacitinib Citrate Extended-Release Tablets Market Size, by Hospital Pharmacy, 2017-2032 (USD Million)
TABLE 135. European Union Tofacitinib Citrate Extended-Release Tablets Market Size, by Retail Pharmacy, 2017-2032 (USD Million)
TABLE 136. European Union Tofacitinib Citrate Extended-Release Tablets Market Size, by Specialty Pharmacy, 2017-2032 (USD Million)
TABLE 137. European Union Tofacitinib Citrate Extended-Release Tablets Market Size, by End User, 2017-2032 (USD Million)
TABLE 138. BRICS Tofacitinib Citrate Extended-Release Tablets Market Size, by Group, 2017-2032 (USD Million)
TABLE 139. BRICS Tofacitinib Citrate Extended-Release Tablets Market Size, by Indication, 2017-2032 (USD Million)
TABLE 140. BRICS Tofacitinib Citrate Extended-Release Tablets Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 141. BRICS Tofacitinib Citrate Extended-Release Tablets Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 142. BRICS Tofacitinib Citrate Extended-Release Tablets Market Size, by Hospital Pharmacy, 2017-2032 (USD Million)
TABLE 143. BRICS Tofacitinib Citrate Extended-Release Tablets Market Size, by Retail Pharmacy, 2017-2032 (USD Million)
TABLE 144. BRICS Tofacitinib Citrate Extended-Release Tablets Market Size, by Specialty Pharmacy, 2017-2032 (USD Million)
TABLE 145. BRICS Tofacitinib Citrate Extended-Release Tablets Market Size, by End User, 2017-2032 (USD Million)
TABLE 146. G7 Tofacitinib Citrate Extended-Release Tablets Market Size, by Group, 2017-2032 (USD Million)
TABLE 147. G7 Tofacitinib Citrate Extended-Release Tablets Market Size, by Indication, 2017-2032 (USD Million)
TABLE 148. G7 Tofacitinib Citrate Extended-Release Tablets Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 149. G7 Tofacitinib Citrate Extended-Release Tablets Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 150. G7 Tofacitinib Citrate Extended-Release Tablets Market Size, by Hospital Pharmacy, 2017-2032 (USD Million)
TABLE 151. G7 Tofacitinib Citrate Extended-Release Tablets Market Size, by Retail Pharmacy, 2017-2032 (USD Million)
TABLE 152. G7 Tofacitinib Citrate Extended-Release Tablets Market Size, by Specialty Pharmacy, 2017-2032 (USD Million)
TABLE 153. G7 Tofacitinib Citrate Extended-Release Tablets Market Size, by End User, 2017-2032 (USD Million)
TABLE 154. NATO Tofacitinib Citrate Extended-Release Tablets Market Size, by Group, 2017-2032 (USD Million)
TABLE 155. NATO Tofacitinib Citrate Extended-Release Tablets Market Size, by Indication, 2017-2032 (USD Million)
TABLE 156. NATO Tofacitinib Citrate Extended-Release Tablets Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 157. NATO Tofacitinib Citrate Extended-Release Tablets Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 158. NATO Tofacitinib Citrate Extended-Release Tablets Market Size, by Hospital Pharmacy, 2017-2032 (USD Million)
TABLE 159. NATO Tofacitinib Citrate Extended-Release Tablets Market Size, by Retail Pharmacy, 2017-2032 (USD Million)
TABLE 160. NATO Tofacitinib Citrate Extended-Release Tablets Market Size, by Specialty Pharmacy, 2017-2032 (USD Million)
TABLE 161. NATO Tofacitinib Citrate Extended-Release Tablets Market Size, by End User, 2017-2032 (USD Million)
TABLE 162. Global Tofacitinib Citrate Extended-Release Tablets Market Size, by Country, 2017-2032 (USD Million)
TABLE 163. United States Tofacitinib Citrate Extended-Release Tablets Market Size, 2017-2032 (USD Million)
TABLE 164. United States Tofacitinib Citrate Extended-Release Tablets Market Size, by Indication, 2017-2032 (USD Million)
TABLE 165. United States Tofacitinib Citrate Extended-Release Tablets Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 166. United States Tofacitinib Citrate Extended-Release Tablets Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 167. United States Tofacitinib Citrate Extended-Release Tablets Market Size, by Hospital Pharmacy, 2017-2032 (USD Million)
TABLE 168. United States Tofacitinib Citrate Extended-Release Tablets Market Size, by Retail Pharmacy, 2017-2032 (USD Million)
TABLE 169. United States Tofacitinib Citrate Extended-Release Tablets Market Size, by Specialty Pharmacy, 2017-2032 (USD Million)
TABLE 170. United States Tofacitinib Citrate Extended-Release Tablets Market Size, by End User, 2017-2032 (USD Million)
TABLE 171. Canada Tofacitinib Citrate Extended-Release Tablets Market Size, 2017-2032 (USD Million)
TABLE 172. Canada Tofacitinib Citrate Extended-Release Tablets Market Size, by Indication, 2017-2032 (USD Million)
TABLE 173. Canada Tofacitinib Citrate Extended-Release Tablets Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 174. Canada Tofacitinib Citrate Extended-Release Tablets Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 175. Canada Tofacitinib Citrate Extended-Release Tablets Market Size, by Hospital Pharmacy, 2017-2032 (USD Million)
TABLE 176. Canada Tofacitinib Citrate Extended-Release Tablets Market Size, by Retail Pharmacy, 2017-2032 (USD Million)
TABLE 177. Canada Tofacitinib Citrate Extended-Release Tablets Market Size, by Specialty Pharmacy, 2017-2032 (USD Million)
TABLE 178. Canada Tofacitinib Citrate Extended-Release Tablets Market Size, by End User, 2017-2032 (USD Million)
TABLE 179. Mexico Tofacitinib Citrate Extended-Release Tablets Market Size, 2017-2032 (USD Million)
TABLE 180. Mexico Tofacitinib Citrate Extended-Release Tablets Market Size, by Indication, 2017-2032 (USD Million)
TABLE 181. Mexico Tofacitinib Citrate Extended-Release Tablets Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 182. Mexico Tofacitinib Citrate Extended-Release Tablets Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 183. Mexico Tofacitinib Citrate Extended-Release Tablets Market Size, by Hospital Pharmacy, 2017-2032 (USD Million)
TABLE 184. Mexico Tofacitinib Citrate Extended-Release Tablets Market Size, by Retail Pharmacy, 2017-2032 (USD Million)
TABLE 185. Mexico Tofacitinib Citrate Extended-Release Tablets Market Size, by Specialty Pharmacy, 2017-2032 (USD Million)
TABLE 186. Mexico Tofacitinib Citrate Extended-Release Tablets Market Size, by End User, 2017-2032 (USD Million)
TABLE 187. Brazil Tofacitinib Citrate Extended-Release Tablets Market Size, 2017-2032 (USD Million)
TABLE 188. Brazil Tofacitinib Citrate Extended-Release Tablets Market Size, by Indication, 2017-2032 (USD Million)
TABLE 189. Brazil Tofacitinib Citrate Extended-Release Tablets Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 190. Brazil Tofacitinib Citrate Extended-Release Tablets Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 191. Brazil Tofacitinib Citrate Extended-Release Tablets Market Size, by Hospital Pharmacy, 2017-2032 (USD Million)
TABLE 192. Brazil Tofacitinib Citrate Extended-Release Tablets Market Size, by Retail Pharmacy, 2017-2032 (USD Million)
TABLE 193. Brazil Tofacitinib Citrate Extended-Release Tablets Market Size, by Specialty Pharmacy, 2017-2032 (USD Million)
TABLE 194. Brazil Tofacitinib Citrate Extended-Release Tablets Market Size, by End User, 2017-2032 (USD Million)
TABLE 195. United Kingdom Tofacitinib Citrate Extended-Release Tablets Market Size, 2017-2032 (USD Million)
TABLE 196. United Kingdom Tofacitinib Citrate Extended-Release Tablets Market Size, by Indication, 2017-2032 (USD Million)
TABLE 197. United Kingdom Tofacitinib Citrate Extended-Release Tablets Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 198. United Kingdom Tofacitinib Citrate Extended-Release Tablets Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 199. United Kingdom Tofacitinib Citrate Extended-Release Tablets Market Size, by Hospital Pharmacy, 2017-2032 (USD Million)
TABLE 200. United Kingdom Tofacitinib Citrate Extended-Release Tablets Market Size, by Retail Pharmacy, 2017-2032 (USD Million)
TABLE 201. United Kingdom Tofacitinib Citrate Extended-Release Tablets Market Size, by Specialty Pharmacy, 2017-2032 (USD Million)
TABLE 202. United Kingdom Tofacitinib Citrate Extended-Release Tablets Market Size, by End User, 2017-2032 (USD Million)
TABLE 203. Germany Tofacitinib Citrate Extended-Release Tablets Market Size, 2017-2032 (USD Million)
TABLE 204. Germany Tofacitinib Citrate Extended-Release Tablets Market Size, by Indication, 2017-2032 (USD Million)
TABLE 205. Germany Tofacitinib Citrate Extended-Release Tablets Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 206. Germany Tofacitinib Citrate Extended-Release Tablets Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 207. Germany Tofacitinib Citrate Extended-Release Tablets Market Size, by Hospital Pharmacy, 2017-2032 (USD Million)
TABLE 208. Germany Tofacitinib Citrate Extended-Release Tablets Market Size, by Retail Pharmacy, 2017-2032 (USD Million)
TABLE 209. Germany Tofacitinib Citrate Extended-Release Tablets Market Size, by Specialty Pharmacy, 2017-2032 (USD Million)
TABLE 210. Germany Tofacitinib Citrate Extended-Release Tablets Market Size, by End User, 2017-2032 (USD Million)
TABLE 211. France Tofacitinib Citrate Extended-Release Tablets Market Size, 2017-2032 (USD Million)
TABLE 212. France Tofacitinib Citrate Extended-Release Tablets Market Size, by Indication, 2017-2032 (USD Million)
TABLE 213. France Tofacitinib Citrate Extended-Release Tablets Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 214. France Tofacitinib Citrate Extended-Release Tablets Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 215. France Tofacitinib Citrate Extended-Release Tablets Market Size, by Hospital Pharmacy, 2017-2032 (USD Million)
TABLE 216. France Tofacitinib Citrate Extended-Release Tablets Market Size, by Retail Pharmacy, 2017-2032 (USD Million)
TABLE 217. France Tofacitinib Citrate Extended-Release Tablets Market Size, by Specialty Pharmacy, 2017-2032 (USD Million)
TABLE 218. France Tofacitinib Citrate Extended-Release Tablets Market Size, by End User, 2017-2032 (USD Million)
TABLE 219. Russia Tofacitinib Citrate Extended-Release Tablets Market Size, 2017-2032 (USD Million)
TABLE 220. Russia Tofacitinib Citrate Extended-Release Tablets Market Size, by Indication, 2017-2032 (USD Million)
TABLE 221. Russia Tofacitinib Citrate Extended-Release Tablets Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 222. Russia Tofacitinib Citrate Extended-Release Tablets Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 223. Russia Tofacitinib Citrate Extended-Release Tablets Market Size, by Hospital Pharmacy, 2017-2032 (USD Million)
TABLE 224. Russia Tofacitinib Citrate Extended-Release Tablets Market Size, by Retail Pharmacy, 2017-2032 (USD Million)
TABLE 225. Russia Tofacitinib Citrate Extended-Release Tablets Market Size, by Specialty Pharmacy, 2017-2032 (USD Million)
TABLE 226. Russia Tofacitinib Citrate Extended-Release Tablets Market Size, by End User, 2017-2032 (USD Million)
TABLE 227. Italy Tofacitinib Citrate Extended-Release Tablets Market Size, 2017-2032 (USD Million)
TABLE 228. Italy Tofacitinib Citrate Extended-Release Tablets Market Size, by Indication, 2017-2032 (USD Million)
TABLE 229. Italy Tofacitinib Citrate Extended-Release Tablets Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 230. Italy Tofacitinib Citrate Extended-Release Tablets Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 231. Italy Tofacitinib Citrate Extended-Release Tablets Market Size, by Hospital Pharmacy, 2017-2032 (USD Million)
TABLE 232. Italy Tofacitinib Citrate Extended-Release Tablets Market Size, by Retail Pharmacy, 2017-2032 (USD Million)
TABLE 233. Italy Tofacitinib Citrate Extended-Release Tablets Market Size, by Specialty Pharmacy, 2017-2032 (USD Million)
TABLE 234. Italy Tofacitinib Citrate Extended-Release Tablets Market Size, by End User, 2017-2032 (USD Million)
TABLE 235. Spain Tofacitinib Citrate Extended-Release Tablets Market Size, 2017-2032 (USD Million)
TABLE 236. Spain Tofacitinib Citrate Extended-Release Tablets Market Size, by Indication, 2017-2032 (USD Million)
TABLE 237. Spain Tofacitinib Citrate Extended-Release Tablets Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 238. Spain Tofacitinib Citrate Extended-Release Tablets Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 239. Spain Tofacitinib Citrate Extended-Release Tablets Market Size, by Hospital Pharmacy, 2017-2032 (USD Million)
TABLE 240. Spain Tofacitinib Citrate Extended-Release Tablets Market Size, by Retail Pharmacy, 2017-2032 (USD Million)
TABLE 241. Spain Tofacitinib Citrate Extended-Release Tablets Market Size, by Specialty Pharmacy, 2017-2032 (USD Million)
TABLE 242. Spain Tofacitinib Citrate Extended-Release Tablets Market Size, by End User, 2017-2032 (USD Million)
TABLE 243. China Tofacitinib Citrate Extended-Release Tablets Market Size, 2017-2032 (USD Million)
TABLE 244. China Tofacitinib Citrate Extended-Release Tablets Market Size, by Indication, 2017-2032 (USD Million)
TABLE 245. China Tofacitinib Citrate Extended-Release Tablets Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 246. China Tofacitinib Citrate Extended-Release Tablets Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 247. China Tofacitinib Citrate Extended-Release Tablets Market Size, by Hospital Pharmacy, 2017-2032 (USD Million)
TABLE 248. China Tofacitinib Citrate Extended-Release Tablets Market Size, by Retail Pharmacy, 2017-2032 (USD Million)
TABLE 249. China Tofacitinib Citrate Extended-Release Tablets Market Size, by Specialty Pharmacy, 2017-2032 (USD Million)
TABLE 250. China Tofacitinib Citrate Extended-Release Tablets Market Size, by End User, 2017-2032 (USD Million)
TABLE 251. India Tofacitinib Citrate Extended-Release Tablets Market Size, 2017-2032 (USD Million)
TABLE 252. India Tofacitinib Citrate Extended-Release Tablets Market Size, by Indication, 2017-2032 (USD Million)
TABLE 253. India Tofacitinib Citrate Extended-Release Tablets Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 254. India Tofacitinib Citrate Extended-Release Tablets Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 255. India Tofacitinib Citrate Extended-Release Tablets Market Size, by Hospital Pharmacy, 2017-2032 (USD Million)
TABLE 256. India Tofacitinib Citrate Extended-Release Tablets Market Size, by Retail Pharmacy, 2017-2032 (USD Million)
TABLE 257. India Tofacitinib Citrate Extended-Release Tablets Market Size, by Specialty Pharmacy, 2017-2032 (USD Million)
TABLE 258. India Tofacitinib Citrate Extended-Release Tablets Market Size, by End User, 2017-2032 (USD Million)
TABLE 259. Japan Tofacitinib Citrate Extended-Release Tablets Market Size, 2017-2032 (USD Million)
TABLE 260. Japan Tofacitinib Citrate Extended-Release Tablets Market Size, by Indication, 2017-2032 (USD Million)
TABLE 261. Japan Tofacitinib Citrate Extended-Release Tablets Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 262. Japan Tofacitinib Citrate Extended-Release Tablets Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 263. Japan Tofacitinib Citrate Extended-Release Tablets Market Size, by Hospital Pharmacy, 2017-2032 (USD Million)
TABLE 264. Japan Tofacitinib Citrate Extended-Release Tablets Market Size, by Retail Pharmacy, 2017-2032 (USD Million)
TABLE 265. Japan Tofacitinib Citrate Extended-Release Tablets Market Size, by Specialty Pharmacy, 2017-2032 (USD Million)
TABLE 266. Japan Tofacitinib Citrate Extended-Release Tablets Market Size, by End User, 2017-2032 (USD Million)
TABLE 267. Australia Tofacitinib Citrate Extended-Release Tablets Market Size, 2017-2032 (USD Million)
TABLE 268. Australia Tofacitinib Citrate Extended-Release Tablets Market Size, by Indication, 2017-2032 (USD Million)
TABLE 269. Australia Tofacitinib Citrate Extended-Release Tablets Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 270. Australia Tofacitinib Citrate Extended-Release Tablets Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 271. Australia Tofacitinib Citrate Extended-Release Tablets Market Size, by Hospital Pharmacy, 2017-2032 (USD Million)
TABLE 272. Australia Tofacitinib Citrate Extended-Release Tablets Market Size, by Retail Pharmacy, 2017-2032 (USD Million)
TABLE 273. Australia Tofacitinib Citrate Extended-Release Tablets Market Size, by Specialty Pharmacy, 2017-2032 (USD Million)
TABLE 274. Australia Tofacitinib Citrate Extended-Release Tablets Market Size, by End User, 2017-2032 (USD Million)
TABLE 275. South Korea Tofacitinib Citrate Extended-Release Tablets Market Size, 2017-2032 (USD Million)
TABLE 276. South Korea Tofacitinib Citrate Extended-Release Tablets Market Size, by Indication, 2017-2032 (USD Million)
TABLE 277. South Korea Tofacitinib Citrate Extended-Release Tablets Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 278. South Korea Tofacitinib Citrate Extended-Release Tablets Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 279. South Korea Tofacitinib Citrate Extended-Release Tablets Market Size, by Hospital Pharmacy, 2017-2032 (USD Million)
TABLE 280. South Korea Tofacitinib Citrate Extended-Release Tablets Market Size, by Retail Pharmacy, 2017-2032 (USD Million)
TABLE 281. South Korea Tofacitinib Citrate Extended-Release Tablets Market Size, by Specialty Pharmacy, 2017-2032 (USD Million)
TABLE 282. South Korea Tofacitinib Citrate Extended-Release Tablets Market Size, by End User, 2017-2032 (USD Million)
TABLE 283. Global Tofacitinib Citrate Extended-Release Tablets Market Share, by Key Player, 2025
TABLE 284. Global Tofacitinib Citrate Extended-Release Tablets Market, Key Experts

Companies Mentioned

  • Apotex Corp.
  • Aurobindo Pharma Limited
  • Cipla Limited
  • Delvin Formulations Pvt Ltd.
  • Dr. Reddy’s Laboratories Limited
  • Glenmark Pharmaceuticals Limited
  • Lupin Limited
  • Mylan Pharmaceuticals, Inc.
  • Pfizer Inc.
  • Sandoz Inc.
  • Teva Pharmaceuticals USA, Inc.

Related Topics

Related Reports

Tofacitinib Citrate Drugs Market - Global Forecast 2026-2032 - Product Image

Tofacitinib Citrate Drugs Market - Global Forecast 2026-2032

  • Report
  • 183 Pages
  • Global
From
Tofacitinib Market Outlook 2025-2034: Market Share, and Growth Analysis - Product Image

Tofacitinib Market Outlook 2025-2034: Market Share, and Growth Analysis

  • Report
  • 160 Pages
  • Global
From
Clomifene Citrate Tablets Market - Global Forecast 2026-2032 - Product Image

Clomifene Citrate Tablets Market - Global Forecast 2026-2032

  • Report
  • 185 Pages
  • Global
From
Tofacitinib Market Report 2026 - Product Image

Tofacitinib Market Report 2026

  • Report
  • 250 Pages
  • Global
From
2025 Global Forecast for Tofacitinib Market (2026-2031): High Tech Outlook Report - Product Image

2025 Global Forecast for Tofacitinib Market (2026-2031): High Tech Outlook Report

  • Report
  • 132 Pages
  • Global
From
Copyright © 2002-2026 Research and Markets. All Rights Reserved.